Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene Posts $1.7M in Revenues for Q3

NEW YORK (GenomeWeb News) – Med BioGene today reported third-quarter revenues of C$1.7 million (US$1.7 million), compared to no revenues for the third quarter of 2010.

The Vancouver, British Columbia-based firm derived all of its revenues from licensing. During the quarter it received license fees and research reimbursement of C$2.3 million from Precision Therapeutics, "half of which is credited against future royalties" that it may receive from Precision, Med BioGene said in a statement accompanying its results.

Earlier this year Med BioGene inked an exclusive licensing deal with Precision Therapeutics covering its LungExpress Dx test. The gene expression-based test has been developed to identify patients with early-stage non-small-cell lung cancer, who following surgical removal of their tumors, are at higher or lower risks of mortality.

Under terms of the agreement, Precision Therapeutics agreed to pay Med BioGene C$2.3 million in licensing fees and research reimbursements within 120 days of the deal's closing. Med BioGene is also eligible for royalty payments.

Med BioGene reported net income of C$1.6 million, or C$.02 per share, for the quarter, compared to a net loss of C$1.7 million, or C$.02 per share, for Q3 2010.

Its R&D spending for the quarter plummeted to C$14,511 from C$194,224, and its general and administrative costs fell sharply to C$183,958 from C$1.5 million.

Med BioGene finished the quarter with C$853,317 in cash and cash equivalents.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.